Wartec

Quick links to important sections

Wartec

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Wartec

Wartec Quick Facts

Property Description
Active ingredient Podofilox
Form Topical cream, Cutaneous solution
Pharmacological class Antimitotic Agent (Topical Cytotoxic)
General Purpose Localized destruction of abnormal tissue
Origin Semi-synthetic derivative of podophyllotoxin

What Type of Medicine is Wartec?

Wartec is a localized, prescription-only pharmaceutical preparation classified as an antimitotic agent and a topical cytotoxic compound. This classification indicates its primary function is to inhibit cell division and induce cell death in targeted, rapidly proliferating tissue. The specific formulation of Wartec is clinically recognized as a primary topical treatment approach.

Wartec's Active Ingredient: Composition, Origin, and Form

The core substance in Wartec is the active ingredient Podofilox (INN). Podofilox is a semi-synthetic derivative of podophyllotoxin, a naturally occurring lignan found in the roots of certain Podophyllum plants. The medicine is strictly for external use and is manufactured in two primary dosage forms: a cutaneous solution and a topical cream. The availability of both a solution and a cream provides flexibility in application depending on the size and location of the affected area.

General Purpose and Cellular Action

The general purpose of Wartec is to promote the destruction and subsequent removal of specific lesions characterized by abnormal, uncontrolled cellular growth. The drug's mechanism involves arresting the cell cycle during mitosis, which leads to the subsequent death and breakdown of the targeted tissue. This localized, destructive action is the core reason for using this type of pharmaceutical preparation, focusing the potent effect only on the abnormal area.

What side effects are possible with Wartec?

Possible Side Effects and Safety Information

The safety profile for Wartec (Podofilox) is predominantly characterized by adverse reactions occurring at the application site, which are organized and classified in regulatory documents.

Officially Documented Adverse Reactions

Side effects are categorized based on frequency observed in clinical use, reflecting the drug's intended localized, cytotoxic action on the skin and subcutaneous tissue.

Frequency Classification Examples of Adverse Reactions (SOC Grouping)
Very Common (ge 1/10) Application site pain, burning sensation, erythema, pruritus, and skin erosion.
Common (ge 1/100 to < 1/10) Application site ulceration, bleeding, edema, crusting, discomfort, and systemic effects like headache or dizziness.

Local irritation, burning, and pain are explicitly noted in regulatory safety notes to be most prominent during the first few days of treatment. Other documented application site effects include skin discoloration, blistering, dry skin, and excoriation.

Serious Safety Constraints and Population Notes

The primary safety constraint is the potential for Severe Systemic Toxicity. This is a documented risk should the product be applied to large surface areas, used excessively, or ingested, which could lead to severe effects on the Nervous and Hematological Systems. To mitigate this risk, regulatory labels mandate strict limitations on the total area and volume of the medicine applied daily.

Population-Specific Limitations state that Wartec is generally not recommended for use in pediatric patients (under 18 years of age) as safety has not been established. Furthermore, its use is often contraindicated or strongly advised against during pregnancy and lactation due to the drug's antimitotic nature and potential for harm.

Overdose and Emergency Response

The official regulatory documents for Wartec (Podofilox) define overdose as a risk primarily resulting from systemic absorption, which occurs after accidental ingestion or excessive topical use. Applying the medication to large surface areas, exceeding the recommended frequency, or using it on compromised skin increases the potential for the drug to enter the bloodstream.

Documented Overdose Manifestations

Classification Manifestations and Outcomes (Regulatory Listed)
Systemic Manifestations Nausea, vomiting, diarrhea, oral ulcers, fever, and altered mental status.
Severe Outcomes Bone marrow depression, renal failure, liver failure (hepatotoxicity), seizures, coma, and respiratory failure.

When Immediate Medical Help is Required

The prescribing information mandates specific actions based on the route of exposure:

  • Accidental Swallowing: Contact emergency services or a Poison Control Center immediately.
  • Topical Over-Application: Stop treatment and contact a healthcare professional if severe local reactions such as bleeding, swelling, or excessive pain, burning, or itching occur.

Treatment for overdose is strictly symptomatic and supportive, as no specific antidote is documented in the labeling. Management includes washing the affected skin area and providing close monitoring of laboratory parameters such as the blood picture, liver function, and electrolyte balance to manage potential systemic toxicity.

Therapeutic Uses of Wartec

What Wartec treats: Main Uses and Benefits

The therapeutic application of Wartec (Podofilox) is focused on addressing symptoms related to localized abnormal tissue and providing subsequent supportive relief. The medication is commonly used for the topical management of external anogenital warts (Condylomata acuminata), a condition characterized by episodic or fluctuating manifestations.

Wartec is relevant in clinical settings that involve acute or unstable symptom patterns, specifically addressing visible epithelial growths and providing supportive care for symptoms related to inflammatory or irritative states. It may assist with the process of visible reduction of external lesions, which contributes to easing discomfort during periods of heightened symptoms. The principal indication is for anogenital warts and perianal warts that manifest as soft, flesh-colored papules.

“This specialized topical therapy supports the patient during difficult episodes by easing the overall symptom burden and assisting with maintaining functional stability.”


Quick Fact: Relief for Localized Skin Lesions

Category Description
Primary Use Applicable in conditions presenting with significant symptomatic burden (anogenital warts).
Symptom Focus Itching, burning, and irritation associated with the presence of localized skin growths.
Patient Benefit Supports the process of visible reduction and helps improve day-to-day comfort during symptomatic periods.
Context of Use Applied in clinical settings that involve acute or unstable symptom patterns, where localized symptomatic assistance is needed.

Regulatory References

  1. DailyMed: Podofilox Topical Solution 0.5% Rx Only

Eligibility and Restrictions for Use

Who Can and Cannot Use Wartec?

Wartec (Podofilox) eligibility is strictly defined by regulatory guidelines based on the patient's status and the local treatment site.

Contraindicated Populations and Conditions

The medicine is contraindicated and must not be used in patients with a known hypersensitivity to podofilox or any component of the formulation. Use is contraindicated in pregnant women due to its antimitotic properties, and some authorities also contraindicate use in breastfeeding mothers and children under 12 years of age. Furthermore, Wartec must not be applied to open wounds, inflamed, or bleeding lesions, or to any lesions suspected to be Squamous Cell Carcinoma.

Specific Restrictions and Limitations

The medicine is only indicated for adults (18 years and older). Safety and effectiveness have not been established in pediatric patients. Use is restricted based on the size of the affected area, which must not exceed 10 cm^2 of wart tissue. The product is not indicated for treatment of warts on mucous membranes of the genital area (including the urethra, rectum, or vagina). Some official monographs advise against use in patients with Diabetes or poor blood circulation.

What should I know about interactions with other medicines?

The official regulatory interaction profile for Wartec (Podofilox) is highly limited due to its topical administration and minimal systemic absorption. The profile's primary documented concern is a single, critical restriction involving the co-administration of similar local treatments.

Interaction Category Official Regulatory Statement
Contraindicated Combinations Other podophyllin-containing preparations.
Mechanistic Basis of Interaction Additive systemic toxicity with other podophyllin derivatives, which may lead to overdose. This is classified as a pharmacodynamic interaction risk.
Systemic Drug-Drug Interactions None documented for co-administered systemic medicines. Regulatory labels indicate that interactions with oral or injectable medications are not known or not expected.
Food, Alcohol, or Herbal Products No known interactions are formally documented with food, alcohol, or herbal products.

The interaction is classified as a Contraindication due to the potential for additive toxic effects at the application site or through systemic absorption. Beyond this prohibition, regulatory documentation establishes that no known systemic drug-drug interactions are anticipated, which directly reflects the medicine's route of administration. The profile does not contain specific timing rules for separating administration from other medicines. This entire structure is based solely on the official regulatory prescribing information from authorities.

Mechanism of Action

Wartec (podophyllotoxin) exerts a direct, localized cytotoxic effect by interfering with the cellular division cycle of rapidly proliferating cells. The drug functions as a spindle poison, binding specifically to the tubulin protein subunits that form microtubules. This interaction inhibits the polymerization of tubulin, preventing the formation of the mitotic spindle necessary for chromosome separation. The failure to form a functional spindle leads to mitotic arrest at the metaphase stage of the cell cycle. This irreversible cellular arrest triggers subsequent cascades that result in necrosis (cell death) of the target cells. The consequence of this localized mechanism is the cessation of cellular proliferation, leading to the physical cellular breakdown and tissue erosion at the site of action, which results in tissue loss. The action is strictly peripheral.

Dosage and Administration Information

Official Administration Regimen

Wartec (Podofilox) is administered exclusively via the topical route as either a 0.5% cutaneous solution or gel formulation. This localized administration approach requires applying the minimum amount necessary to cover the affected lesion, with the total area treated generally restricted to less than 10~ cm^2 per application. The use protocol mandates that the preparation is applied directly to the tissue while avoiding contact with the surrounding, healthy skin.

Frequency and Duration

The standard regimen follows a defined intermittent cycle as defined for this preparation. The medicine is applied twice daily—typically in the morning and evening—for 3 consecutive days. This application period is then followed by a mandatory 4 consecutive days of rest with no application, completing one full treatment cycle.

To ensure use within established parameters, the total daily quantity of the preparation must not exceed 0.5~ mL of solution or 0.5~ g of gel. The full course of therapy is strictly limited to a maximum of four total treatment cycles. If the desired response is not achieved after the final cycle, treatment should be discontinued. Additionally, the safety and effectiveness of this medicine have not been established for use in the pediatric population.

Recent Clinical Evidence

Research evidence / Overview of studies for Wartec (Podofilox)

Evidence for Use in External Anogenital Warts

The research base for Wartec (Podofilox) primarily involves randomized controlled trials (RCTs). These studies were conducted during periods of increased symptom activity and applied in research contexts involving fluctuating or unstable symptoms. The research examined whether the topical application of Wartec, compared to a non-active gel or solution (placebo), was associated with changes in the lesions.

The primary outcomes studied involved the physical manifestation of the condition. Researchers monitored the change in the total number of lesions and, most importantly, measured the attainment of study-defined clearance of all visible lesions by the end of the short-term study periods. The patient populations in these trials were primarily adults aged 18 and older with clinically diagnosed external warts.

Studies reported how symptoms evolved in the observed populations; measurements of study-defined lesion clearance varied across trials. Findings describe patterns observed in the studies where clearance rates were measured between the Podofilox groups and the vehicle-only groups. Research provides insight into short-term changes; however, these findings describe group patterns, not personal outcomes.

Study Comparison: Podofilox versus Other Topical Treatments

Research also examined Wartec in comparison to other topical prescription treatments studied for the same condition. These studies monitored outcomes related to physical discomfort and outcomes reflecting daily functioning. They compared how different therapies performed in terms of lesion clearance and local skin reactions.

Systematic reviews and comprehensive analyses have been completed that synthesize data from many individual trials. This evidence contributes to the broader understanding of symptom patterns by showing how Wartec was evaluated against other active treatments.

Durability of Study Findings and Recurrence Patterns

A critical component of the research is tracking the persistence of the initial study findings. After patients achieved study-defined clearance of the lesions, studies observed responses over defined time intervals to see if the lesions returned. The frequency and rate of new lesion development, known as recurrence, was a key outcome monitored in the months following successful treatment.

Studies conducted during the follow-up period monitored lesion recurrence, which was frequently observed, with findings being mixed and highly variable across different studies. Some research explored the use of Wartec as a prophylactic measure—meaning it was applied at the site of cleared warts—and this data showed different measurements of recurrence compared to placebo application in that specific scenario.

Evidence in Special Patient Groups

Evidence describing the experience and outcomes of Wartec in special patient groups remains limited. The vast majority of the research included populations studied: non-immunocompromised adults. Data for certain groups remain insufficient, particularly for the pediatric population (children). Limited information is available for long-term outcomes in older adults. Current core evidence describes group patterns, not personal outcomes, for these populations.

Key Studies & References

  1. Podofilox Topical Solution 0.5% - FDA Approved Labeling (DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Wartec (FAQ)

Q: Can Wartec be used on internal areas of the body?

A: Official product information emphasizes that this medicine is strictly for topical use on the skin only. Regulatory guidelines indicate it is not intended for use inside the body or on mucous membranes such as the urethra, rectum, or vagina, to avoid irritation and potential absorption.


Q: Does Wartec need a prescription in most places?

A: Wartec is classified as a prescription-only pharmaceutical preparation in the regions where it has been approved. This means official information requires it to be dispensed only with a doctor's valid prescription.


Q: Can Wartec interact with other skincare products or creams?

A: Regulatory documents prioritize the primary restriction against using the medicine alongside other podophyllin-containing preparations due to the risk of additive toxicity. Interactions with systemic medications or non-podophyllin cosmetic/skincare products are not formally documented. This information is generally provided by the patient to their healthcare professional for review.


Q: Is it possible to use Wartec for long periods of time?

A: Official information defines the course of therapy using structured, intermittent cycles. The total use is strictly limited to a maximum of four total treatment cycles, and safety and effectiveness have not been studied or established for use beyond this specified duration.


Q: Can Wartec be used alongside oral medications?

A: Because the medicine is applied topically and systemic absorption is minimal, regulatory labels indicate that interactions with co-administered oral or injectable medications are not known or not anticipated.


Q: What are the general guidelines for using Wartec near mucous membranes?

A: The medicine is not indicated for use on mucous membranes, which includes areas like the inside of the rectum or vagina. This restriction is in place because application to these sensitive tissues may cause severe irritation.


Q: Does Wartec affect the appearance of skin scars?

A: Regulatory reports compiled from clinical use and post-marketing data have noted the occurrence of scarring of treated skin as a possible adverse effect. This outcome is generally related to the drug’s localized action causing cellular breakdown and tissue erosion.


Q: Is it safe to use Wartec if I have an open cut nearby?

A: The official guidelines state that the medicine is contraindicated and is not intended for use on skin with existing conditions such as open wounds, inflamed, or bleeding lesions. Application near open cuts aligns with this core restriction.


Q: Are there specific patient characteristics that make Wartec eligibility uncertain?

A: Official monographs describe limitations or restrictions for patients with certain pre-existing conditions. These characteristics include poor blood circulation and diabetes.


Q: Is Wartec known to cause systemic side effects, based on regulatory information?

A: While local effects are common, regulatory information reports less common systemic effects such as headache and dizziness. Excessive use or large-area application carries a documented risk of severe systemic toxicity.


Q: What is the purpose of the application method described for Wartec?

A: The detailed application method, including strict limits on the total area and volume used, is designed to maximize the drug's localized effect on the target tissue. It also serves to minimize contact with the normal surrounding skin to reduce the risk of severe irritation and unwanted systemic absorption.


Q: What should be avoided during the treatment period when using Wartec?

A: Official documents state that the medicine is not intended for use with other podophyllin-containing preparations. Additionally, it is intended to avoid contact with healthy skin or the eyes/nose/mouth, and should not be covered with bandages or waterproof dressings.


Q: Can Wartec be used by people with sensitive skin?

A: Regulatory documents list inactive ingredients, known as excipients, that include components such as sorbic acid, stearyl alcohol, and cetyl alcohol. These excipients may cause local skin reactions such as contact dermatitis.


Q: Does Wartec contain any known allergens?

A: Yes, official regulatory documents list excipients like methyl and propyl parahydroxybenzoate that may cause allergic reactions. A known hypersensitivity to the active substance or any component of the formulation is listed as a contraindication.


Q: Is Wartec treatment considered permanent, or can the condition return?

A: Official information notes that Wartec is not a cure for the underlying condition. Recurrence of the lesions is a known possibility, and patients may develop new lesions during or following the end of treatment.


Q: What should be done if Wartec is accidentally swallowed?

A: Official safety guidance indicates that in the event the medicine is swallowed, the procedure involves contacting a local poison control center or emergency services immediately. This is due to the documented risk of severe systemic toxicity from ingestion.


Q: Are there specific activities or conditions that might interfere with Wartec's use?

A: Official warnings specify that sexual intercourse is not intended to take place on the days the gel or solution is applied to the lesions. This is to help prevent drug contact with sensitive areas and mucous membranes.


Q: Are there different strengths of Wartec available?

A: The concentration for the active ingredient, Podofilox, is most commonly available in a 0.5% strength. This is the concentration for the solution and gel formulations referred to in the regulatory documentation.


Q: What evidence exists regarding Wartec's use in combination with other treatments?

A: The strongest evidence is the contraindication against using Wartec with other podophyllin-containing preparations due to the risk of additive toxicity. Beyond this prohibition, regulatory labels indicate no known systemic interactions are anticipated.


Q: Is Wartec known to cause changes in skin color?

A: Yes, regulatory documents and post-marketing data have listed skin discoloration as a possible adverse drug reaction. This is one of the local skin effects that may occur in the treated area.


Q: Are there specific storage and disposal requirements for Wartec that make it hazardous waste?

A: The solution formulation is noted to be flammable and must be stored away from fire and excessive heat. Regulatory guidelines for unused medicine involve disposal by following national guidelines or returning it to a pharmacist.


Q: Do studies suggest Wartec works better on certain body parts?

A: Clinical research has noted that the initial solution formulation may be unsuitable for women and for anal warts due to potential irritation. The cream formulation was developed specifically to provide an alternative formulation for use at those sensitive sites.


Q: Is Wartec suitable for people with a history of seizures or nervous system disorders?

A: Regulatory information reports that systemic effects can include dizziness and sleep problems (insomnia). Furthermore, severe systemic toxicity from overdose is officially associated with potential effects on the nervous system.


Q: What is the difference between the Wartec solution and the cream?

A: The difference primarily relates to application comfort and suitability for different areas. Clinical use indicated the solution was sometimes considered unsuitable for women and for anal warts due to the vehicle, and the cream formulation was developed to provide an alternative option for those specific, sensitive sites.


Q: What are the general rules for traveling with Wartec, especially the solution?

A: Regulatory warnings state that the solution is flammable. For storage and transit, it must be kept in its original, tightly closed container, stored at room temperature, and kept away from fire, flame, and excessive heat.

How should Wartec be stored and disposed of?

Storage and Disposal of Wartec

Wartec (Podofilox) must be stored under specific environmental and temperature controls as defined in its official labeling to maintain product stability.

Labeled Storage Requirements

Condition Regulatory Requirement
Temperature Store Wartec Solution at controlled room temperature (15 C to 30 C) and Cream below 30 C.
Prohibitions Do not freeze or refrigerate either formulation.
Protection Solution is flammable; keep away from fire, flame, and excessive heat. Keep containers tightly closed and away from moisture.
Child Safety Must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Wartec product must not be disposed of in household trash or down the toilet. Patients are directed to return any leftover medicine to a pharmacist for proper disposal. The Podofilox Solution may have specific regulatory requirements for disposal as a hazardous waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Wartec found in:

A-Z Index: